The liver helps regulate one of medical sciences' four humours in the blood and Royal Society Enterprise Fund has backed OrganOx.

The Royal Society Enterprise Fund, a quasi-corporate venturing fund, has joined a consortium investing £2.75m ($5m) in OrganOx, a UK-based medical device manufacturer to increase the number of human livers available for transplant.  

OrganOx was spun out of the University of Oxford by Isis Innovation in 2008 and had venture capital firms Oxford Technology Management and Technikos as its initial investors.

Last month, the Royal Society fund joined a £1.6m round backing Novacem, a carbon-negative cement company, alongside contruction…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?